Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of lazertinib and pemetrexed in EGFR-mutant NSCLC patients with leptomeningeal carcinomatosis
KCT0005919Phase 2Completed
- Sponsor
- Korean Cancer Study Group
- Start
- Jan 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lazertinib, pemetrexed in non-small cell lung cancer (NSCLC), Carcinomatous Meningitis (CM), sponsored by Korean Cancer Study Group. Started Jan 2022; status: completed.
02
Drugs
lazertinibpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)Carcinomatous Meningitis (CM)
Beyond the preview
Go deeper on KCT0005919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005919.